


Supplementary Information

*for*

**Gene-diet interactions associated with complex trait variation  
in an advanced intercross outbred mouse line**


*Vorobyev, Gupta & Sezin et al.*




**Supplementary Fig 1. Diversity of the micro- and mycobiota in NZM2410/J lupus prone mice.** **a** Alpha diversity (Chao1 index) of the mycobiota between mice set on different diets across naïve, transient and final stages of disease stratified based on diet ( $n_{\text{caloric restriction}}=12$  mice,  $n_{\text{control diet}}=12$  mice, and  $n_{\text{western diet}}=10$  mice, left panel) or based on the presence ( $n=15$  mice) or absence ( $n=19$  mice) of disease (right panel). Data is presented as mean  $\pm$  SEM and statistical significance was assessed using Kruskal-Wallis test with Mann-Whitney U test as a post hoc test. **b** PCoA plots present microbial beta diversity (unweighted UniFrac distance) when the data on the microbiota are stratified based on diet ( $n_{\text{caloric restriction}}=18$  mice,  $n_{\text{control diet}}=17$  mice, and  $n_{\text{western diet}}=20$  mice, left panel) or based on the presence ( $n=24$  mice) or absence ( $n=31$  mice) of disease (right panel) at the transient stage of disease. **c** Similarly, PCoA plots for the mycobiota (Jaccard distance) for stratification of the data based on diet ( $n_{\text{caloric restriction}}=11$  mice,  $n_{\text{control diet}}=11$  mice, and  $n_{\text{western diet}}=9$  mice, left panel) or disease presence ( $n=13$  mice) and absence ( $n=18$  mice) (right panel) in the transient stage are shown. Data were assessed using the adonis function in R (permutations=999) by comparing centroids. Source data for (a-c) are provided as a Source Data file.




**Supplementary Fig 2.** LEfSe bar plots of micro- and mycobiotic taxonomic biomarkers for different diets and based on presence/absence of disease. The features are plotted as color-coded bars on a logarithmic scale of linear discriminant analysis (LDA) scores. The features were considered statistically significant if  $\log_{10}$  of the LDA score  $> 1.5$  and if the Kruskal-Wallis test (for diet) or Mann-Whitney U test (for disease) yields a P-value  $< 0.05$ . Bar plots in (a) and (b) show LDA scores for three diets for the mycobiome at the transient and final stages of disease, respectively. Bar plots in (c) and (d) depict LDA scores for diseased versus non-diseased mice for the mycobiome at the transient and final stages of disease, respectively. Similarly, LDA scores in bar plots (e) and (f) are shown for stratification of the microbiota data based on diets in the transient and final stages, respectively. LDA scores for microbiota data in diseased versus non-diseased mice in the transient (g) and final stages (h) of disease are shown. Source data for (a-h) are provided as a Source Data file.



b







**Supplementary Fig 4.** Boxplot (the band indicates the median, the box indicates the first and third quartiles and whiskers indicate 1.5\*interquartile range) showing the eigengene values on the y-axis and functional communities of bacteria (a) and fungi (b) on the x-axis, stratified based on the absence ( $n_{FMC} = 37$  mice,  $n_{FFC} = 18$  mice) or presence ( $n_{FMC} = 16$  mice,  $n_{FFC} = 16$  mice) of antinuclear antibody in NZM2410/J mice. Statistical significance was assessed using the Mann-Whitney U test and adjusted for multiple testing by the Benjamini-Hochberg correction. \* $P_{adj} < 0.05$ . Source data for (a,b) are provided as a Source Data file.



Phenotypes	Unit	Assessment method	N	$\sigma$ sex (%)	$\sigma$ diet (%)
<i>Physiological phenotypes</i>					
<i>Metabolic phenotypes</i>					
Body weight (final)	g	Weighting at 6 months	1,064	5.52	47.94
- body weight (month 2)	g	Weighting at 2 months	777	8.07	33.67
- body weight (month 4)	g	Weighting at 4 months	779	7.25	45.5
Spleen weight	g	Weighting at 6 months	1,065	0.81	14.21
Total cholesterol	mg/dl	ELISA	853	0.61	14.75
HDL <sup>1</sup> cholesterol	mg/dl	ELISA	835	1.06	13.14
LDL cholesterol	mg/dl	ELISA	853	0.1	8.75
<i>Hematological phenotypes</i>					
WBC	K/ $\mu$ l	HemaVet	467	1.42	1.13
Neutrophils	K/ $\mu$ l	HemaVet	467	0.12	0.21
Lymphocytes	K/ $\mu$ l	HemaVet	467	1.66	2.68
Monocytes	K/ $\mu$ l	HemaVet	467	2.45	0.34
Eosinophils	K/ $\mu$ l	HemaVet	467	2.18	4.22
Basophils	K/ $\mu$ l	HemaVet	467	1.2	1.69
Neutrophils / WBC	%	HemaVet	467	0.48	3.4
Lymphocytes / WBC	%	HemaVet	467	0.05	4.55
Monocytes / WBC	%	HemaVet	467	0.97	0.09
Eosinophils / WBC	%	HemaVet	467	1.44	5.73
Basophils / WBC	%	HemaVet	467	2.47	3.4
RBC	M/ $\mu$ l	HemaVet	467	0.99	0.08
Hb	g/dL	HemaVet	467	0.48	0.07
HCT	%	HemaVet	467	0.2	0.64
MCV	fL	HemaVet	467	0.07	1.93
MCH	pg	HemaVet	467	0.17	0.03
MCHC	g/dL	HemaVet	467	0	2.43
RDW	%	HemaVet	467	3.19	3.42
Platelets	K/ $\mu$ l	HemaVet	467	1.72	1.97
MPV	fL	HemaVet	467	0.38	1.44
<i>Immunoglobulins</i>					
IgA serum concentration	mg/ml	ELISA	534	0.55	19.14
IgG serum concentration	mg/ml	ELISA	534	4.1	2.11
IgM serum concentration	mg/ml	ELISA	534	0.69	26.19
IgA x G x M serum concentration	mg/ml	ELISA	534	0.46	0.19
(IgA x IgG) / IgM	-	ELISA	534	0.07	28.63
IgA x IgG	-	ELISA	534	0.06	9.08
IgA / IgG	-	ELISA	534	2.96	24.58
IgA / IgM	-	ELISA	534	1.02	37.02
IgG / IgM	-	ELISA	534	0.17	18.74
<i>Glycosylation patterns</i>					
IgG – G0	%	HILIC-HPLC	699	0.46	6.72
IgG – G1	%	HILIC-HPLC	699	0.65	12.53
IgG – G2	%	HILIC-HPLC	699	0.27	4.22

IgG - G1S1	%	HILIC-HPLC	699	0.59	5.24
IgG – G2S1	%	HILIC-HPLC	699	0.13	0.1
IgG – G2S2	%	HILIC-HPLC	699	0.56	0.77
IgG – presence of terminal galactose	%	HILIC-HPLC	699	0.67	12.45
IgG – total galactosylated	%	HILIC-HPLC	699	0.46	6.72
IgG – monogalactosylated	%	HILIC-HPLC	699	0.42	9.84
IgG – bigalactosylated	%	HILIC-HPLC	699	0.22	1.17
IgG – total sialylated	%	HILIC-HPLC	699	0	0.38
IgG sialylated/galactosylated	-	HILIC-HPLC	699	0.08	4.96
<i>Others</i>					
Coat colour	Binary	Visual	1,154	0.06	0
<b><i>Pathophysiological phenotypes</i></b>					
CRP	pg/ml	ELISA	435	1.64	14.56
ANA	Binary	IF on Hep-20-10 cells	1,113	0.57	4.28
NAFLD	Score	assessment of H&E stained sections	653	1.63	41.41
<i>Balloning</i>	<i>As above</i>	assessment of H&E stained sections	653	3.43	46.43
<i>Steatosis</i>	<i>As above</i>	assessment of H&E stained sections	653	0.4	28.28
<i>NASH</i>	<i>As above</i>	assessment of H&E stained sections	653	0.09	11.63

- "N" indicates number of mice

- Abbreviations: HDL: high-density lipoproteins; LDL: low-density lipoprotein; CRP: C-reactive protein; WBC: white blood cells; RBC: red blood cells; Hb: haemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin concentration; RDW: red cell distribution width; MPV: mean platelet volume; PDW: platelet distribution width; Ig: immunoglobulin; ANA: anti-nuclear antibodies; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis, ELISA: enzyme-linked immunosorbent assay; HILIC-HPLC: hydrophilic interaction liquid chromatography-high performance liquid chromatography; IF: immunofluorescence; H&E: haemotoxylin and eosin;

**Supplementary Table 1.** Overview of the investigated traits. Detailed information concerning the different assessment methods is available in the Methods section.

<b>Pathways enriched in diseased samples</b>			
<i>Reactome pathways</i>	<i>Number of Genes</i>	<i>P-value</i>	<i>FDR</i>
Activation of C3 and C5 (R-MMU-174577)	4	0.00000588	0.000365
Alternative complement activation (R-MMU-173736)	3	0.00013	0.00699
CD22 mediated BCR regulation (R-MMU-5690714)	14	9.98E-15	1.47E-12
FCGR activation (R-MMU-2029481)	17	1.62E-17	4.37E-15
Scavenging of heme from plasma (R-MMU-2168880)	18	2.06E-18	1.11E-15
Initial triggering of complement (R-MMU-166663)	18	6.64E-18	2.15E-15
Classical antibody-mediated complement activation (R-MMU-173623)	14	4.07E-14	5.48E-12
Role of phospholipids in phagocytosis (R-MMU-2029485)	17	1.27E-16	2.57E-14
Binding and Uptake of Ligands by Scavenger Receptors (R-MMU-2173782)	19	3.07E-18	1.24E-15
Role of LAT2/NTAL/LAB on calcium mobilization (R-MMU-2730905)	13	7.58E-13	7.65E-11
Creation of C4 and C2 activators (R-MMU-166786)	14	1.44E-13	1.67E-11
Regulation of Complement cascade (R-MMU-977606)	21	1.09E-19	1.76E-16
Complement cascade (R-MMU-166658)	21	6.11E-19	4.93E-16
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers (R-MMU-983695)	14	6.55E-13	7.06E-11
FCERI mediated Ca <sup>2+</sup> mobilization (R-MMU-2871809)	13	7.20E-12	6.13E-10
FCERI mediated MAPK activation (R-MMU-2871796)	13	1.64E-11	1.33E-09
Regulation of actin dynamics for phagocytic cup formation (R-MMU-2029482)	17	6.47E-14	8.05E-12
Fc gamma receptor (FCGR) dependent phagocytosis (R-MMU-2029480)	19	7.02E-15	1.14E-12
FCERI mediated NF-κB activation (R-MMU-2871837)	13	3.72E-09	2.86E-07
Cell surface interactions at the vascular wall (R-MMU-202733)	19	1.44E-12	1.29E-10
Signaling by the B Cell Receptor (BCR) (R-MMU-983705)	14	6.66E-09	4.68E-07
Fc epsilon receptor (FCERI) signaling (R-MMU-2454202)	13	0.000000133	0.00000894
Peptide ligand-binding receptors (R-MMU-375276)	11	0.0000188	0.00109
Post-translational protein phosphorylation (R-MMU-8957275)	7	0.000869	0.0401
Hemostasis (R-MMU-109582)	33	8.22E-13	7.82E-11

Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) (R-MMU-381426)	8	0.000732	0.0348
Innate Immune System (R-MMU-168249)	49	4.62E-16	8.30E-14
Neutrophil degranulation (R-MMU-6798695)	26	6.50E-09	4.78E-07
Class A/1 (Rhodopsin-like receptors) (R-MMU-373076)	14	0.000033	0.00184
Immune System (R-MMU-168256)	67	3.26E-17	7.53E-15
G alpha (i) signalling events (R-MMU-418594)	14	0.000229	0.0116
GPCR ligand binding (R-MMU-500792)	15	0.000198	0.0103
Vesicle-mediated transport (R-MMU-5653656)	23	0.00000511	0.00033
Cytokine Signaling in Immune system (R-MMU-1280215)	14	0.000556	0.0272
Adaptive Immune System (R-MMU-1280218)	24	0.000018	0.00108

---

**Pathways enriched in healthy samples**

---

<i>Reactome pathways</i>	<i>Number of Genes</i>	<i>P-value</i>	<i>FDR</i>
Butyrophilin (BTN) family interactions (R-MMU-8851680)	11	6.44E-06	1.04E-02
CD209 (DC-SIGN) signaling (R-MMU-5621575)	4	8.60E-05	4.63E-02

**Supplementary Table 2.** Pathways enrichment in healthy vs. disease states

Components	Control diet (S0587-E001)	Atherogenic diet (S0587-E020)
Casein, %	18,600	18,600
Soy protein isolate, %	—	—
Gelatine, %	—	—
Corn starch, pre-gelat., %	40,000	10,000
Maltodextrin, 10 DE, %	13,940	9,690
Sucrose, %	10,000	30,000
pur. Cellulose powder, %	5,000	5,000
L-Lysine HCl	—	—
L-Threonine	—	—
L-Tryptophan	—	—
L-Cystine	0,200	0,200
DL-Methionine	0,100	0,100
L-Histidine HCl H <sub>2</sub> O, %	—	—
Vitamin premix, AIN93G, %	1,000	1,000
Mineral premix, AIN93G, %	3,500	3,500
Choline Cl, %	0,250	0,250
Ca hydrogenphosphate, %	0,400	0,500
BHT, %	0,010	0,010
Cholesterol, %	—	0,150
Butter fat, %	—	20,000
Soybean oil, %	7,000	1,000
Crude protein, %	16,6	16,6
Crude fat, %	7,1	21,0
Crude fibre, %	5,0	5,0
Crude ash, %	3,4	3,5
Starch, %	39,9	9,8
Sugar, %	11,2	31,0
Lysine, %	1,36	1,36
Methionine, %	0,61	0,61
Cystine, %	0,27	0,27
Met + Cys, %	0,88	0,88
Threonine, %	0,72	0,72
Tryptophan, %	0,22	0,22
Arginine, %	0,64	0,64
Histidine, %	0,50	0,50
Valine, %	1,14	1,14
Isoleucine, %	0,93	0,93
Leucine, %	1,63	1,63
Phenylalanine, %	0,85	0,85
Phe+Tyr, %	1,72	1,72

**Supplementary Table 3:** Composition of diets used in the study

**Microbiome forward primers**

27F-MID-1	AATGATACGGCGACCACCGAGATCTACACAACCGCATTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-2	AATGATACGGCGACCACCGAGATCTACACAAGGCCTTTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-3	AATGATACGGCGACCACCGAGATCTACACAGAGTGTGTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-4	AATGATACGGCGACCACCGAGATCTACACCACAAGTCTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-5	AATGATACGGCGACCACCGAGATCTACACCGTTCCTATATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-6	AATGATACGGCGACCACCGAGATCTACACGCTTGGATTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-7	AATGATACGGCGACCACCGAGATCTACACGTCAACACTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-8	AATGATACGGCGACCACCGAGATCTACACGCTCACTGATATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-9	AATGATACGGCGACCACCGAGATCTACACTCTCGTCATATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-10	AATGATACGGCGACCACCGAGATCTACACTTGGTACGTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-11	AATGATACGGCGACCACCGAGATCTACACCGTGGATTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-12	AATGATACGGCGACCACCGAGATCTACACCGTAAAGCTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-13	AATGATACGGCGACCACCGAGATCTACACACAGCTCATATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-14	AATGATACGGCGACCACCGAGATCTACACGACAAGTGTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-15	AATGATACGGCGACCACCGAGATCTACACGCATTAGCTATGGTAATTGTAGAGTTTGATCCTGGCTCAG
27F-MID-16	AATGATACGGCGACCACCGAGATCTACACTGTGGACTTATGGTAATTGTAGAGTTTGATCCTGGCTCAG

**Microbiome reverse primers**

338R-MID-A	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-B	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-C	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-D	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-E	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-F	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-G	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-H	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-I	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-J	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-K	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-L	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-M	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-N	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-O	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-P	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-Q	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-R	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-S	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-T	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-U	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-V	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-W	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT
338R-MID-X	CAAGCAGAAGACGGCATAACCGGAAAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT

## Sequencing primers

16SRead.1. TATGGTAATTGTAGAGTTTGATCCTGGCTCAG  
16SRead.2. AGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT  
16SIndex ACTCTACGGGAGGCAGCAGGCTGACTGACT

## Mycobiome forward primers

ITSF.SB501 AATGATACGGCGACCACCGAGATCTACACCTACTATATATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB502 AATGATACGGCGACCACCGAGATCTACACCGTACTATATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB503 AATGATACGGCGACCACCGAGATCTACACAGAGTCACTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB504 AATGATACGGCGACCACCGAGATCTACACTACGAGACTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB505 AATGATACGGCGACCACCGAGATCTACACACGTCTCGTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB506 AATGATACGGCGACCACCGAGATCTACACTCGACGAGTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB507 AATGATACGGCGACCACCGAGATCTACACGATCGTGTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB508 AATGATACGGCGACCACCGAGATCTACACGTCAGATATATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB509 AATGATACGGCGACCACCGAGATCTACACCTGAAGTCTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB510 AATGATACGGCGACCACCGAGATCTACACACGATCGTTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB511 AATGATACGGCGACCACCGAGATCTACACATATGGCCTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB512 AATGATACGGCGACCACCGAGATCTACACTTCGATGGTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB513 AATGATACGGCGACCACCGAGATCTACACTTGGTACGTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB514 AATGATACGGCGACCACCGAGATCTACACCGTTGGATTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB515 AATGATACGGCGACCACCGAGATCTACACCGTAAAGCTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB516 AATGATACGGCGACCACCGAGATCTACACACAGCTCATATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB517 AATGATACGGCGACCACCGAGATCTACACGACAAGTGTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB518 AATGATACGGCGACCACCGAGATCTACACGATTAGCTATGGTAATTGGTCCTCCGCTTATTGATATGC  
ITSF.SB519 AATGATACGGCGACCACCGAGATCTACACTGTGGACTTATGGTAATTGGTCCTCCGCTTATTGATATGC

## Mycobiome reverse primers

ITSR.SA701 CAAGCAGAAGACGGCATAACGAGATAACTCTCGAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA702 CAAGCAGAAGACGGCATAACGAGATACTATGTCAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA703 CAAGCAGAAGACGGCATAACGAGATAGTAGCGTAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA704 CAAGCAGAAGACGGCATAACGAGATCAGTGAGTAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA705 CAAGCAGAAGACGGCATAACGAGATCGTACTCAAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA706 CAAGCAGAAGACGGCATAACGAGATCTACGACAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA707 CAAGCAGAAGACGGCATAACGAGATGGAGACTAAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA708 CAAGCAGAAGACGGCATAACGAGATGTCGCTCGAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA709 CAAGCAGAAGACGGCATAACGAGATGTCGTAGTAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA710 CAAGCAGAAGACGGCATAACGAGATTAGCAGACAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA711 CAAGCAGAAGACGGCATAACGAGATTCATAGACAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA712 CAAGCAGAAGACGGCATAACGAGATTCGCTATAAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA713 CAAGCAGAAGACGGCATAACGAGATTACGTACGAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA714 CAAGCAGAAGACGGCATAACGAGATGATCACGTAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA715 CAAGCAGAAGACGGCATAACGAGATGTGACAGAAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA716 CAAGCAGAAGACGGCATAACGAGATAACCGGAAAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA717 CAAGCAGAAGACGGCATAACGAGATCAACTGGTAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA718 CAAGCAGAAGACGGCATAACGAGATCGTTCGTTAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA719 CAAGCAGAAGACGGCATAACGAGATCTGTTACAGTCAGTCAGCCGTGARTCATCGAATCTTTG  
ITSR.SA720 CAAGCAGAAGACGGCATAACGAGATGCTTGCAAAGTCAGTCAGCCGTGARTCATCGAATCTTTG

ITSR.SA721	CAAGCAGAAGACGGCATAACGAGATGTCAACTGAGTCAGTCAGCCGTGARTCATCGAATCTTTG
ITSR.SA722	CAAGCAGAAGACGGCATAACGAGATTCCTCATGAGTCAGTCAGCCGTGARTCATCGAATCTTTG
ITSR.SA723	CAAGCAGAAGACGGCATAACGAGATTTGCAAGCAGTCAGTCAGCCGTGARTCATCGAATCTTTG
ITSR.SA724	CAAGCAGAAGACGGCATAACGAGATACACCTCTAGTCAGTCAGCCGTGARTCATCGAATCTTTG

**Sequencing  
primers**

ITSRead.1.	TATGGTAATTGGTCCTCCGCTTATTGATATGC
ITSRead.2.	AGTCAGTCAGCCGTGARTCATCGAATCTTTG
ITSIndex	CAAAGATTGATGARTCACGGCTGACTGACT

**Supplementary Table 4.** A list of all primer sequences that were used for NGS sequencing of the 16S rRNA and ITS2 genes in our study.